Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer-Reference-Cited by-同舟云学术

Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer

Published:2014-01-16 Issue:2 Volume:19 Page:135-150
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Eroglu Zeynep¹,Tagawa Tomoko²,Somlo George¹

Affiliation:

1. City of Hope Comprehensive Cancer Center, Duarte, California, USA;

2. Harbor-UCLA Medical Center, Torrance, California, USA

Abstract

Learning Objectives Describe the role of HER2 in breast cancer pathogenesis. List the approved and investigational agents targeting the HER receptor family and downstream signaling pathways with focus on overcoming resistance to HER2-targeted therapies. Describe ongoing clinical trials evaluating the efficacy and safety of agents targeting HER and downstream pathways in breast cancer patients.

Funder

Boehringer Ingelheim Pharmaceuticals

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://pericles-gcp.literatumonline.com/doi/pdf/10.1634/theoncologist.2013-0283

Reference126 articles.

1. Anti-EGFR therapy: Mechanism and advances in clinical efficacy in breast cancer;Flynn;J Oncol,2009

2. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients;Sassen;Breast Cancer Res,2008